AIM ImmunoTech Inc. — Proxy Solicitation & Information Statement 2022

Sep 26, 2022

DEFA14A 1 formdefa14a.htm

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934 (Amendment No. )

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

| ☐ | Preliminary
Proxy Statement |
| --- | --- |
| ☐ | Confidential,
for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive
Proxy Statement |
| ☒ | Definitive
Additional Materials |
| ☐ | Soliciting
Material under § 240.14a-12 |

AIM ImmunoTech Inc.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

| ☒ | No
fee required |
| --- | --- |
| ☐ | Fee
paid previously with preliminary materials |
| ☐ | Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

On September 26, 2022, AIM ImmunoTech Inc. (the “Company”) began mailing the below mailer to stockholders of the Company along with copies of the Amendment No. 1 to the Company’s Definitive Proxy Statement and accompanying revised WHITE proxy card, which were filed with the U.S. Securities and Exchange Commission on September 21, 2022.

Field: Page; Sequence: 3; Options: Last

Field: /Page